Dr. Kamel Khalili is the Laura H. Carnell Professor and Chair of the Department of Neuroscience, and Director of the Center for Neurovirology at the Lewis Katz School of Medicine at Temple University. He is also director of the Comprehensive NeuroAIDS Center and Co-Director of the Center for Translational NeuroAIDS Research. Dr. Khalili has been actively studying the molecular neuropathogenesis of viral-induced diseases for more than thirty years, most notably HIV-1/AIDS. By concentrating on the mechanism involved in regulation of HIV-1 gene transcription and replication in several cell models, he has made several important discoveries related to LTR interaction with host factors, development of small inhibitory molecules for suppressing viral replication, the interaction of HIV-1 with other pathogens (most notably JCV) in brain, and the mechanism for reactivation of this JCV by HIV-1 and the development of PML in brain of AIDS patients. More recently, he and his colleagues have developed a gene editing strategy to successfully eradicate HIV-1 in human cell cultures and animal models toward a cure for AIDS. In addition, his technology has shown promising results for protecting cells from HIV-1 infection.
Dr. Khalili has published more than 427 scientific papers (170 papers on HIV-1), edited two textbooks related to viral oncology and human polyomaviruses, and has received more than $70 million in funding from the National Institutes of Health during the last thirty years. He has trained more than thirty MD/PhD and PhD students and more than sixty postdoctoral fellows, senior investigators and junior faculty. He is the founder of the International Society of NeuroVirology and the Editor-in-Chief of the Journal of NeuroVirology.